Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.75 (78.87% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016Brean CapitalReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016BTIG ResearchReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.25)$1.64ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.12)($0.12)($0.12)
Q2 20161($0.11)($0.11)($0.11)
Q3 20161$0.52$0.52$0.52
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateHeadline
07/22/16 08:46 AMBBP: An Outperforming Biotechnology ETF
07/22/16 07:48 AMProgenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 - [at noodls] - July 22, 2016 TARRYTOWN, N.Y., July 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and ...
07/21/16 01:22 PMETF’s with exposure to Progenics Pharmaceuticals, Inc. : July 21, 2016 -
07/21/16 08:41 AMBrean Capital Sees 125% Upside for Progenics Pharmaceuticals, Inc. (PGNX) Following FDA Approval for Oral Relistor - Smarter Analyst
07/21/16 08:41 AMProgenics Pharmaceuticals Inc. (PGNX) Jumps 24.29% on July 20 - Equities.com
07/21/16 08:41 AMAnalyst Consideration on this Stock: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle
07/21/16 08:41 AMOptions Volume Explodes as Progenics Pharmaceuticals, Inc. (PGNX) Takes Off - Schaeffers Research (blog)
07/20/16 06:38 PMValeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR
07/20/16 06:38 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX): Our Members Are Already Up 25% In Very Quick Time
07/20/16 06:38 PMOptions Volume Explodes as Progenics Pharmaceuticals, Inc. (PGNX) Takes Off
07/20/16 03:31 PMWhy Progenics Pharmaceuticals, Inc. Shares Soared Today - The biotech scored FDA approval for the oral version of its opioid-induced constipation drug, Relistor.
07/20/16 08:40 AMHeightened Volatility Spotted on Shares of: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - Engelwood Daily
07/20/16 08:40 AMActive biotech company shares in the news: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Cerus Corporation ... - The Voice Registrar
07/20/16 08:36 AMStocks to Watch: Microsoft, Progenics, Valeant, Morgan Stanley, Zafgen, Halliburton -
07/20/16 07:25 AMPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/19/16 07:32 PMValeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics -
07/19/16 05:55 PMShares Losing Ground in Session: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - TGP
07/19/16 05:55 PMValeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR - StreetInsider.com
07/19/16 05:55 PMBiotech news that matter for investors: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Anavex Life Sciences Corp ... - The Voice Registrar
07/19/16 05:25 PMValeant, Progenics shares rise on constipation drug approval -
07/19/16 05:04 PMValeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain - [PR Newswire] - LAVAL, Quebec and TARRYTOWN, N.Y., July 19, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the ...
07/19/16 05:46 AMStock in the Spotlight: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle
07/15/16 04:51 PMShares Experiencing a Downtrend: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - TGP
07/15/16 04:51 PMProgenics Pharmaceuticals Inc. (PGNX) Jumps 5.59% on July 15 - Equities.com
07/15/16 10:56 AMIntraday Active Biotech Stocks News: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Juno Therapeutics Inc ... - The Voice Registrar
07/15/16 10:56 AMProgenics Pharmaceuticals Inc. (PGNX) Drops 5.02% on July 13 - Equities.com
07/14/16 06:06 PMNoteworthy Thursday Option Activity: MIC, PGNX, XPO
07/13/16 06:10 PMActive biotech company shares in the news: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Rock Creek ... - The Voice Registrar
07/13/16 08:45 AMShort Term Rating on Progenics Pharmaceuticals (PGNX) - TheFounders Daily
07/12/16 06:03 PMHot Biotech Stocks Recap: Progenics Pharmaceuticals (NASDAQ:PGNX), ZIOPHARM Oncology (NASDAQ:ZIOP) - The Voice Registrar
07/12/16 06:03 PMStock Performance to Track: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle
07/12/16 08:00 AMTop 3 Biotech Companies Awaiting FDA Approval -
07/11/16 05:49 PMStock Volatility Focus for: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - Engelwood Daily
07/11/16 10:29 AMCompany Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) Rally 23.48% - TheFounders Daily
07/09/16 08:59 AMProgenics Pharmaceuticals, Inc. Stock Momentum Hits Strength - CML News
07/08/16 07:51 AMProgenics Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - July 8, 2016 TARRYTOWN, N.Y., July 08, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating ...
07/08/16 07:30 AMProgenics Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - TARRYTOWN, N.Y., July 08, 2016-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that Mark R. ...
07/07/16 05:52 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) will be presented at the upcoming Society of Nuclear Medicine and ... - Inside Trade
07/07/16 05:52 PMProgenics Pharmaceuticals Inc. (PGNX) Jumps 7.51% on July 07 - Equities.com
07/07/16 08:41 AMUpdated Analysts Rating Report: Medivation, Inc. (NASDAQ:MDVN) , Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Street Updates
07/06/16 06:01 PMShare Volatility in Focus: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - Engelwood Daily
07/06/16 06:01 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s Company Shares Decreased 10.32% After High Volatility - Press Telegraph
07/06/16 06:01 PMAnalyst's Valuable Buzzers: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Progenics Pharmaceuticals Inc ... - Street Updates
07/06/16 06:01 PMStock to Track: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle
07/05/16 12:06 PMValeant Pharmaceuticals: A $1 Billion Opportunity? -
07/03/16 05:09 PMTime to Buy Progenics Pharmaceuticals, Inc. After Today's Huge Increase? - Press Telegraph
07/01/16 08:35 AMRecently Issued Stock Ratings For Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Fiscal Standard
06/30/16 06:04 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Fundamental Star Rating Report - CML News
06/29/16 05:44 PMIs Progenics Pharmaceuticals, Inc.'s Fuel Running Low? The Stock Just Declined Again - Press Telegraph
06/29/16 05:44 PMPerformance Overview of the company: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle

Social

About Progenics Pharmaceuticals

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PGNX
  • CUSIP: 74318710
Key Metrics:
  • Previous Close: $6.16
  • 50 Day Moving Average: $4.89
  • 200 Day Moving Average: $4.70
  • P/E Ratio: N/A
  • P/E Growth: 0.17
  • Market Cap: $420.38M
  • Beta: 2.07
  • Current Year EPS Consensus Estimate: $0.12 EPS
  • Next Year EPS Consensus Estimate: $-0.14 EPS
Additional Links:
Progenics Pharmaceuticals (NASDAQ:PGNX) Chart for Saturday, July, 23, 2016